<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The majority of "serrated pathway" <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> have mutation of the BRAF oncogene and display the CpG island methylator phenotype (CIMP) </plain></SENT>
<SENT sid="1" pm="."><plain>Half these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> have microsatellite instability (MSI) and an excellent prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>In the absence of MSI (microsatellite stable, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>), BRAF mutation has been associated with a particularly poor prognosis. "Traditional pathway" <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are BRAF <z:mp ids='MP_0002169'>wild type</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Mutation of p53 is common and this correlates with advanced stage </plain></SENT>
<SENT sid="4" pm="."><plain>We therefore hypothesized that p53 mutation would be common in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>One thousand and eighty-one <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> were screened for BRAF mutation to identify two BRAF mutant study groups (MSI: n = 77; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>: n = 69) and a BRAF <z:mp ids='MP_0002169'>wild type</z:mp> control group (n = 101) </plain></SENT>
<SENT sid="6" pm="."><plain>These were screened for p53 mutation by high resolution melt analysis and classified for CIMP and MGMT methylation by quantitative methylation specific PCR </plain></SENT>
<SENT sid="7" pm="."><plain>Molecular data were compared to patient age, gender, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location and stage </plain></SENT>
<SENT sid="8" pm="."><plain>p53 was mutated significantly more frequently in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF mutant (28/69, 40.6%) compared to MSI/BRAF mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (13/77, 16.9%), but this mutation rate did not differ from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (47/101, 46.5%)(p &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>CIMP was less common in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF mutant (26/47, 55.3%) compared to MSI/BRAF mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (41/54, 75.9%), but was more common than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (3/85, 3.5%) (p &lt; 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were more commonly proximal (38/54, 70.3%), but were similar to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF <z:mp ids='MP_0002169'>wild type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in terms of patient age, gender distribution and stage at presentation </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>/BRAF mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> share molecular and clinical features of both the serrated and traditional pathways of colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
</text></document>